Europe Nuclear Medicine Diagnostics Market – Share, Outlook, Trends, Size and Forecast (2024 – 2032)

Nuclear Medicine market is that which deals with medicine that utilises radiation to convey data about the functioning of persons particular organs to treat a disease. This market has gained huge popularity all around the world. Inclination and advancement in SPECT and PET analysis for nuclear medicine market and newer computer-based procedures for image analysis and display are boosting the market growth.

Europe Nuclear Medicine Diagnostics Market Segments Size & Growth:

Europe nuclear medicine diagnostics market is expected to reach $ 24.602 billion by 2024 from $ 12.534 billion in 2017 at a CAGR of 12.50% during the forecast 2018-2024. The key factors responsible for the market growth are newer computer-based procedures for image analysis and display, new 99mTc labelled agents for visualising biologically significant events, increasing demand for SPECT and PET analysis development and integration of x-ray tomography into SPECT and so on. However, a shorter lifetime of radioisotopes and reimbursement issues are hampering the market growth.

Europe Nuclear Medicine Diagnostics Market Segments Share:

Europe nuclear medicine diagnostics market is divided into radioisotopes and application. By radioisotopes, the market is categorised into SPECT, PET, beta-emitters, alpha emitters and brachytherapy. Among these SPECT is having the demand and most significant share in the market as they are used in many nuclear applications such as nuclear cardiology procedures. However, SPECT will soon flip upside down due to the shortage of molybdenum-99 which in turn causes a deficiency of technetium-99 as it is by-products are included which are about to have grown during the forecast period. The application is categorised into PET application, therapeutics application and diagnostics application. By geography, Europe is analysed under various regions namely UK, Spain, Italy, Germany, and France.

Europe Nuclear Medicine Diagnostics Market Trends:

• GE Healthcare and Roche diagnostics come together to develop industry-first software integrating in-vivo and in-vitro diagnostics data with latest clinical research for improved patient outcomes.
• Puridify acquired GE Healthcare, and GE Healthcare provides transformational medical technologies and services.
• Gamma Medica announced that CE mark approval was received allowing for sale and distribution of Luma GEM.
• Gamma Medica makes a luma GEM molecular breast imaging system, a patient-friendly cost-effective tool that is poised to revolutionise battle against cancer.
• Gamma Medica partnered with medical imaging Inc. and capital X-Ray, Inc.

Europe Nuclear Medicine Diagnostics Market Research Report:

An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.

To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.

Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year

Identifying DROC in the current market and their impact in altering the market dynamics.

Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial analysis with major competitors.

Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.

The major market players are

• GE Healthcare
• Agfa-gevaert N.V
• Gamma Medica Inc.
• CardiArc Ltd.
• Digirad Corporation